Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough

Eli Lilly has signed a $1.3 billion agreement with Superluminal Medicines to accelerate the discovery and development of AI-powered obesity treatments. The partnership grants Lilly exclusive rights to advance and commercialize new drug candidates identified by Superluminal’s proprietary artificial intelligence platform, which is focused on targeting G-protein-coupled receptors (GPCRs)—key proteins involved in metabolism, cell growth, and immune function.

This move aims to strengthen Lilly’s leadership in the obesity market, valued at $150 billion by the next decade, as competition intensifies with companies like Novo Nordisk. The collaboration will explore oral small-molecule therapies, an area where rivals are also pursuing innovative approaches.

Superluminal, a Boston-based startup, is backed by major investors including RA Capital, Insight Partners, and NVIDIA’s NVentures. While Superluminal is developing its own lead candidate for rare genetic obesity, this asset is not included in the Lilly deal. The partnership includes upfront payments, milestones, equity investment, and tiered royalties on future sales.

Industry leaders highlight that GPCRs represent an underexplored but critical target class for obesity and cardiometabolic disease. Lilly, already dominating with its GLP-1 drugs like Zepbound, is betting on next-generation therapies to maintain its competitive edge.

This landmark agreement signals a new era in AI-driven drug discovery and could reshape the future of obesity treatment worldwide.